Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

In the Media

  • April 28, 2022

Fly exclusive interview with CEO Eric Adams

Leading digital financial news publisher “The Fly” gets an update on the launch of InMed’s rare cannabinoid products and progress of our programs from CEO Eric A. Adams.

Excerpt:

In an exclusive interview with The Fly, InMed Pharmaceuticals (INM) CEO Eric Adams talked about the company, ongoing clinical trials, COVID-related impacts and much more.

DEVELOPMENT COMING ALONG ‘QUITE WELL’: InMed Pharmaceuticals is focused on the development, manufacturing and commercialization of rare cannabinoids across both the pharmaceutical and health and wellness markets. The company is currently developing a cannabinoid synthesis manufacturing system called IntegraSyn to produce cost-effective, pharmaceutical-grade, bio-identical cannabinoids.

“IntegraSyn is one of the several technologies we have in-house here at InMed. We utilize a number of different approaches, including biosynthesis and chemical synthesis. IntegraSyn is kind of an integrated approach between those two to help manufacture certain kinds of cannabinoids. In order to decide which manufacturing approach is best, we need to understand a couple of things. Number 1, what’s the structure of the target cannabinoid we want to make. Number 2, at what quality level we want to make it. Number 3, how much we want to manufacture. Then we can select from our portfolio of different technologies and decide which one is best applicable to our goals. IntegraSyn is one of these. Its development is coming along quite well. We expect to be making larger scale batches well within the next couple of weeks, ” Adams explained to The Fly.

Read the full article in The Fly.

Full Article

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Latest Articles

The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids, like

Read More
May 17, 2022

Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid

Read More
April 28, 2022

Empowered Patient Podcast: Manufacturing Bioidentical Rare Cannabinoids to Treat Glaucoma and Rare Skin Disease with Eric Adams InMed Pharmaceuticals

Empowered Patient Podcast Host Karen Jagoda speaks with InMed CEO Eric A. Adams about the company’s cannabinol programs in glaucoma and epidermolysis bullosa. Excerpt: Eric

Read More
April 11, 2022
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent